Slate Asset Management Appoints Bozena Jankowska as Managing Director and Global Head of ESG
23.11.2021 11:00:00 EET | Business Wire | Press release
Slate Asset Management ("Slate" or “the firm”), a global alternative investment platform focused on real estate, today announced that it has appointed Bozena Jankowska as Managing Director and Global Head of Environmental, Social and Governance (“ESG”), based in Slate’s London office.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211123005469/en/
Bozena Jankowska, Managing Director and Global Head of ESG at Slate Asset Management (Photo: Business Wire)
Jankowska has nearly two decades of experience at the intersection of finance and corporate responsibility. She will lead the development of best-in-class ESG practices and policies aimed at safeguarding the long-term performance of Slate’s global investments. Additionally, Jankowska will oversee and advance Slate’s corporate social responsibility strategy and the integration of ESG into Slate’s investment and asset management processes, as well as stakeholder communications and reporting. Her focus over the next year will be to complete an ESG assessment of Slate’s assets under management, with an initial focus on Europe, before subsequently expanding to the entirety of Slate’s global platform.
“We are very pleased to welcome Bozena to our team,” said Brady Welch, Founding Partner at Slate. “From the outset, Bozena’s commitment to innovation and her entrepreneurial spirit set her apart from other candidates. She led the drive for sustainability in the finance industry well before it became mainstream, and her deep-rooted technical knowledge of complex global sustainability topics will be extremely valuable as we continue driving our ESG strategy forward.”
Blair Welch, Founding Partner at Slate Asset Management, added: “We understand that having sound ESG practices underpinning our approach to investment and asset management benefits our tenants, our communities and our investors. Bozena’s appointment displays our deep commitment to embedding ESG principles across our business.”
Jankowska was Global Co-Head of ESG at Allianz Global Investors (“AGI”), responsible for ESG integration across the firm’s investment portfolio. During her 15-year tenure at AGI, she pioneered a number of innovative ESG strategies and processes, establishing a global ESG team and growing AGI’s total sustainable investment assets under management from €70 million to over €30 billion. She also designed, managed and marketed the Allianz Global Investors clean technology fund – Global Ecotrends – which grew from $10 million in seed funding to $1 billion in assets under management, becoming a global franchise for the firm.
After leaving AGI, Jankowska founded a successful women’s sustainable fashion label, overseeing the brand’s business strategy and creative direction, including sustainable materials research and sourcing, supply chain management, and successful partnerships with non-governmental organizations focused on environmental sustainability.
“I am excited to join an organization that clearly understands how best-in-class ESG practices can play a critical role in long-term value creation,” said Jankowska. “I look forward to working with the team at Slate to continue raising the bar on the firm’s ESG performance and identifying new and innovative ways to add further rigor to our ESG approach.”
Jankowska holds a Bachelor of Science in Environmental Science from the University of Sussex. She completed her Master of Science in Environment Technology with distinction at Imperial College.
Jankowska joined Slate on November 22.
About Slate Asset Management
Slate Asset Management is a global alternative investment platform focused on real estate. We focus on fundamentals with the objective of creating long-term value for our investors and partners. Slate’s platform has a range of investment strategies, including opportunistic, value add, core plus and debt investments. We are supported by exceptional people and flexible capital, which enable us to originate and execute on a wide range of compelling investment opportunities. Visit slateam.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211123005469/en/
Contact information
Slate Asset Management
Karolina Kmiecik
Karolina@slateam.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom